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Gamma-aminobutyric acid (GABA) plays a key role in mammals as the major inhibitory
neurotransmitter of the central nervous system. Although GABA may not be able to
cross the human blood-brain barrier, it was approved as a food ingredient because of its
benefits to the host after oral administration including anti-hypertensive, anti-depressant
and anti-inflammatory activities. Considering the current trend toward the development
of new functional and natural products and that microbial fermentation is one of the
most promising methods to produce this non-protein amino acid, the in situ production
of GABA through fermentation of strawberry and blueberry juices by the efficient GABA
producer strain, Levilactobacillus brevis (formerly known as Lactobacillus brevis) CRL
2013, was evaluated. A high GABA production (262 mM GABA) was obtained after
fermenting strawberry juice supplemented with yeast extract for 168 h, being GABA yield
significantly higher in strawberry juices than in the blueberry ones. Thus, GABA-enriched
fermented strawberry juice (FSJ) was selected to carry out in vivo and in vitro studies.
The in vitro functional analysis of the GABA-enriched FSJ demonstrated its ability to
significantly decrease the expression of cox-2 gene in LPS stimulated RAW 264.7
macrophages. In addition, in vivo studies in mice demonstrated that both, L. brevis CRL
2013 and the GABA-enriched FSJ were capable of reducing the levels of peritoneal,
intestinal and serum TNF-α, IL-6, and CXCL1, and increasing IL-10 and IFN-γ in mice
exposed to an intraperitoneal challenge of LPS. Of note, the GABA-enriched FSJ was
more efficient than the CRL 2013 strain to reduce the pro-inflammatory factors and
enhance IL-10 production. These results indicated that the CRL 2013 strain exerts anti-
inflammatory effects in the context of LPS stimulation and that this effect is potentiated
by fermentation. Our results support the potential use of L. brevis CRL 2013 as an
immunomodulatory starter culture and strawberry juice as a remarkable vegetable
matrix for the manufacture of GABA-enriched fermented functional foods capable of
differentially modulating the inflammatory response triggered by TLR4 activation.
Keywords: GABA, lactic acid bacteria, Levilactobacillus brevis, strawberry fermented juice, anti-inflammatory
properties, TLR4 activation
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INTRODUCTION
Gamma-aminobutyric acid (GABA) is an ubiquitous non-protein
amino acid widely distributed among microorganisms, plants
and animals, having diverse physiological functions and great
potential health benefits (Ramos-Ruiz et al., 2018). GABA
exerts some positive effects on mammalian physiology; such as
hypotensive, relaxation, antidiabetic and immunity enhancement
effects (Adeghate and Ponery, 2002; Abdou et al., 2006; Yang
et al., 2012). Due to its relevance and health benefits, GABA
is becoming recognized as an essential nutrient for a healthy
and balanced diet. GABA has been authenticated as new
resource food by China Food and Drug Administration in
2009 and it is listed in the Chinese Pharmacopeia (Ramos-
Ruiz et al., 2018). Additionally, a healthy diet following the
WHO food-based dietary guidelines (FBDG) and/or the Healthy
Eating Plate (Harvard) will provide a considerable amount of
GABA as a natural nutrient. Nevertheless, GABA content in
natural animal- and plant-based food products is low (Quílez
and Diana, 2017). Therefore, efforts are being devoted to
the development of new technological processes for GABA
enrichment in traditional foods.
Lactic acid bacteria (LAB) are microorganisms that inhabit
nutrient-rich environments associated with food, seeds, plants,
animals, and humans. Due to their Qualified Presumption
of Safety (QPS) status and their use in food, biotechnology,
and therapeutic applications, LAB are highly industrially
relevant microorganisms and represent a multi-billion Euros
business worldwide (Johansen, 2017). Thus, LAB strains,
mainly belonging to Levilactobacillus brevis (formerly known
as Lactobacillus brevis) species, constitute the most competitive
and technologically relevant group of microorganisms used to
synthesize GABA since they are able to produce high levels of
this compound within a variety of food matrices (Park and Oh,
2007; Kim et al., 2009; Wu et al., 2015; Li et al., 2016; Villegas
et al., 2016; Bao et al., 2020; Cui et al., 2020). In this regard, we
have recently demonstrated that L. brevis CRL 2013 is an efficient
microorganism for the conversion of monosodium glutamate
(MSG) to GABA in hexose-supplemented complex media with
conversion ratios about 99% (Cataldo et al., 2020). This GABA
yield was one of the highest values observed among lactobacilli
grown in batch culture (Villegas et al., 2016; Cataldo et al., 2020;
Cui et al., 2020). Then, our results support the potential use of
L. brevis CRL 2013 as a starter culture for the manufacture of
GABA-enriched functional foods.
In dietary guidelines worldwide, an increased consumption
of fruits and vegetables is recommended. The intake of the
so-called “superfruits” like berries that are rich in nutrients,
phytochemicals and constitute important dietary reservoirs of
bioactive compounds can prevent various diseases and disorders
(Nile and Park, 2014). Thus, berries have potent antioxidant,
anticancer, antimutagenic, antimicrobial, anti-inflammatory, and
anti-neurodegenerative properties, both in vitro and in vivo
(Nile and Park, 2014). Among berries, blueberry (Vaccinium
corymbosum) and strawberry (Fragaria x ananassa) are widely
cultivated in Argentina, which is the second largest strawberry
producer in The Common Market of the Southern Cone
(MERCOSUR), being Canada, United States, and the European
Union the main export destinations of Argentinian strawberries.
These fruits are not only available fresh but also generally
consumed frozen and processed into juices, yogurts, beverages,
jams, and jellies. In general, berries have a low GABA content,
ranging from 0.016 mg/g for strawberries to 0.079 mg/g for
blueberries (Ramos-Ruiz et al., 2018). Fortifying beverages with
GABA is being intensively studied due to its potential health
benefits (Kim et al., 2009; Quílez and Diana, 2017). However,
artificially produced GABA cannot be added to food manufacture
since GABA is not a legal additive in several countries; including
countries of the European Union and Argentina [Efsa Panel
on Dietetic Products, and Nutrition, and Allergies [NDA],
2009; Kim et al., 2009]. Then, the use of efficient GABA
producer starter cultures such as L. brevis CRL 2013 to increase
GABA concentrations in berry-juices would be an alternative
to bioenrich these beverages with this bioactive compound.
Therefore, the aims of this work were: (a) to obtain a GABA-
enriched berry juice fermented by the high GABA producer
L. brevis CRL 2013, combining the health benefits of both, GABA
and berries; and (b) to evaluate the potential anti- inflammatory
properties of this GABA-enriched juice by using in vitro and
in vivo approaches in the context of Toll-like receptor (TLR)-4
mediated inflammation.
MATERIALS AND METHODS
Microorganism and Growth Conditions
Levilactobacillus brevis CRL 2013 was isolated from Andean
Real Hornillos quinoa sourdough (Cataldo et al., 2020) and
belongs to the CERELA culture collection (CERELA-CONICET,
Argentina). The strain was routinely propagated and cultivated
in a modified MRS broth (pH 6.5) containing 1% glucose
and 1% fructose instead of 2% glucose. When assessing GABA
production, cells were statically grown in capped test tubes
containing 267 mM of monosodium glutamate (MSG) at 30◦C.
For the juice fermentation assays, eighteen-hour cultures were
harvested by centrifugation (9,000 × g for 10 min), washed
twice with sterile 0.8% (w/v) NaCl and used as inoculums to
reach an initial optical density at 600 nm (OD600) of about 0.1
(approximately 5× 107 CFU/ml).
Determination of GABA Concentration
Gamma-aminobutyric acid was tittered using a modified version
of the GABase method previously described by Tsukatani
et al. (2005). Briefly, 86 mM Tris–HCl buffer (pH 9), 5 mM
α-ketoglutarate, 3.3 mM 2-mercaptoethanol, 1.2 mM NADP+,
and 0.03 U of GABase were added to each well of a 96-well
microtiter plate. The mixture was warmed at 25◦C, and then
the standard or sample solution (fermented juice supernatants)
was added (Cataldo et al., 2020). The NADPH formation was
measured at 340 nm every 1 min for 10 min at 25◦C in a Biotek
Synergy HT microplate reader (Winooski, VT, United States).
GABA concentration in each sample was calculated from
the calibration curve of the standard solutions (0.10, 0.25,
0.50, and 1 mM GABA).
Frontiers in Microbiology | www.frontiersin.org 2 December 2020 | Volume 11 | Article 610016
fmicb-11-610016 December 11, 2020 Time: 21:0 # 3
Cataldo et al. Immunomodulatory Properties of GABA-Enriched Juice
Development of GABA-Enriched
Fermented Juices
Blueberries (Vaccinium corymbosum) and strawberries (Fragaria
x ananassa) harvested in 2018 were purchased from production
fields in Lules (Tucumán, Argentina). For the preparation of
blueberry (BJ) and strawberry (SJ) juices, frozen fruits were
thawed at room temperature for 4 h and then crushed on a
Russell Hobbs JM550SRH Juice extractor (China). Juices were
then centrifuged three times at 14,000 × g for 10 min to get rid
of the remaining pulp and then sterilized at 115◦C for 15 min.
When needed, pulp-free juices were supplemented with 267 mM
MSG, 1% (w/v) yeast extract (YE) or tryptein (T). The initial pH
was either adjusted to approximately 6.5 with 0.1 M NaHCO3 or
left unmodified. All juices were inoculated with L. brevis CRL
2013 to an initial cell density of 5 × 107 CFU/ml. Cell growth
(OD600), pH and GABA production were determined at different
time intervals for 7 days. To determine cell growth, bacterial
culture was washed twice with phosphate buffered solution (PBS)
and resuspended to the original volume using the same solution.
Non-inoculated berry juices processed in the same way as the
sample were used as controls. Juices fermentations were followed
up until the conversion rate from MSG to GABA reached its
maximum values for this strain (around 98%).
Cell Culture
Mouse RAW 264.7 macrophages were obtained from IMBICE,
CONICET (Argentina). Cells were routinely kept in a RPMI
Medium (Genbiotech, Argentina), supplemented with 10%
(w/v) fetal bovine serum (FBS, NATOCOR, Argentina),
penicillin G (100 U/ml, Gibco, ThermoFisher, Argentina),
streptomycin (100 µg/ml, Gibco) and amphotericin B (25 µg/ml,
Gibco) at 37◦C in a humidified 5% CO2-95% air incubator
(standard conditions).
MTT Cell Viability Assay
The influence of GABA-enriched berry juices on cell proliferation
was analyzed by the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide (MTT) assay (Marcial et al.,
2014). Briefly, RAW 264.7 cells were seeded at 5.0 × 104 cells
per well with RPMI containing 10% FBS in 96-well plates and
cultured for 24–48 h at 37◦C in a humidified environment
until 85% of confluence was reached. Then, the medium was
removed, cells were washed twice with PBS and adherent cells
were incubated at 37◦C for 24 h in the presence of GABA (0.1
and 1.0 mM) (Sigma-Aldrich Co., MO, United States), filtrated
dilutions of fermented strawberry juice (FSJ) supernatants to
obtain a final GABA concentration of 1 mM or the same dilution
of the non-fermented strawberry juice (NFSJ). After incubation,
the medium was discarded, cells were washed with PBS and 50 µl
of MTT solution (2.6 mg/ml in PBS) were added in each well
and incubated for 4 h at 37◦C in a 5% CO2 incubator. Living
cells convert MTT into a purple colored formazan product.
MTT was removed from the plates and 50 µl DMSO/well
were added to dissolve the formazan crystals. After 5 min
the absorbance at 570 nm, which is directly proportional to
the cellular metabolism, was measured in a Biotek Synergy HT
microplate reader (Winooski, VT, United States) and cell viability
was estimated as the percentage absorbance of sample relative to
the positive control.
RT-qPCR
RAW 264.7 cells were inoculated in 6-well plates
(0.5 × 106 cells/ml) and incubated as described above for
24–48 h. At 85% confluence, the medium was replaced with fresh
media containing GABA (0.1 or 1 mM), filtrated dilutions of
FSJ supernatants to obtain a final GABA concentration of 1 mM
or the same dilution of the NFSJ, and cells were pre-incubated
for 1 h at 37◦C. Then, cells were treated with 1 µg/ml of
lipopolysaccharide (LPS) for 4 h to induce the inflammatory
state. Adherent cells were harvested after the LPS stimulation
and total RNA was isolated using the TRIzol reagent following
the manufacturer’s instructions (Life Technologies, Buenos
Aires, Argentina). Briefly, cells were lysed in 400 µl of TRIzol;
and 200 µl of chloroform were added to each tube. Finally, the
suspensions were centrifuged for 15 min at 1,2000 × g and 4◦C.
RNA was isolated from the upper hydrophilic phase by adding
100 µl of isopropyl alcohol and allowing it to precipitate for 2 h
at−20◦C. Samples were centrifuged again, the supernatants were
discarded and pellets were washed twice with 70% cold ethanol,
resuspended in 15 µl of RNase-free water and stored at −80◦C.
Total RNA was quantified using the Qubit RNA HS assay kit
(Life technologies). The reverse transcription was carried out
employing the SuperScript III First Strand Kit (Life technologies)
following the supplier’s instructions.
The specific oligonucleotides sequences for cyclooxygenase
(cox-2) gene and β-actin used in this study were previously
described by Chang et al. (2016). Real Time qPCR was performed
on an iQ5 Real-Time PCR Detection System (BioRad) with the
IQTM SYBR R©supermix (Bio-Rad) in 96-well plates. PCR was
performed with 1 µl of cDNA (100 ng) or water in the non-
template controls, 4 µl of primer mix (0.3 µM of each primer),
5 µl of RNase-free water and 10 µl of IQTM SYBR R©supermix
as described by Brown et al. (2017). The PCR cycles consisted
in: 95◦C for 4 min, 40 cycles of 95◦C for 15 seg, 52◦C for
30 seg, 72◦C for 30 seg and 95◦C for one-minute. A non-template
control was included within each PCR reaction. Amplification
efficiencies were validated and normalized against the β-actin
gene. A melting curve analysis was performed immediately at
the end of each experiment at a linear temperature transition
rate of 0.1◦C/s from 55 to 95◦C to determine the specificity of
the amplification. The relative mRNA expression (as fold change)
was determined using β-actin as normalizing housekeeping gene
by the 2−11CT or Livak method (Livak and Schmittgen, 2001).
Animals and Feeding Procedures
Male 4-week-old Balb/c mice were obtained from the closed
colony kept at CERELA (Tucuman, Argentina). They were
housed in plastic cages with controlled room temperature
(22 ± 2◦C temperature, 55 ± 2% humidity) and were fed
ad libitum conventional balanced diet. This study was carried out
in strict accordance with the recommendations of the Guide for
the Care and Use of Laboratory Animals of the Guidelines for
Animal Experimentation of CERELA. The CERELA Institutional
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Animal Care and Use Committee prospectively approved this
research under the protocol BIOT-CRL-17.
Mice were housed individually during the experiments and the
assays for each parameter studied were performed in five mice
per group. L. brevis CRL 2013 was administered to mice for 3
consecutive days at a dose of 2 × 108 cells/mouse/day in the
drinking water (4 ml per mice per day). Different groups of mice
were also treated with GABA-enriched fermented strawberry
juice (FSJ) containing ∼140 mM GABA or diluted (1:2) GABA-
enriched FSJ containing ∼70 mM GABA [FSJ + CRL2013 and
FSJ + CRL2013 (d), respectively] during 3 consecutive days
ad libitum. The GABA-enriched fermented strawberry juice
(FSJ + CRL2013) contains about 2.7 × 107 CFU/ml. Groups
of mice treated with non-fermented strawberry juice (NFSJ)
or NFSJ supplemented with yeast extract (NFSJ + YE) were
used as controls. One day after the end of the treatments, mice
were challenged with LPS to induce inflammation as described
previously (Garcia-Castillo et al., 2019). Mice received 8 mg/kg
of LPS from Escherichia coli O55:B5 by intraperitoneal injection.
Cytokine Concentrations
The concentration of cytokines was determined in peritoneal
fluid, blood and intestinal samples. Peritoneal fluid was collected
from mice as described previously (Garcia-Castillo et al., 2019).
Blood samples were obtained through cardiac puncture at the end
of each treatment and collected in heparinized tubes. Intestinal
fluid samples were obtained by separating the small intestine
and flushing it with 5 ml of PBS. The fluid was centrifuged
(10,000× g, 4◦C for 10 min) to separate particulate material. The
supernatant was kept frozen until use. Blood and tissue samples
were obtained from mice after the intraperitoneal injection of
ketamine (80 mg/kg) and xylazine (10 mg/kg) according to the
recommendations of the CERELA Institutional Animal Care
and Use Committee.
Tumor necrosis factor α (TNF-α), interferon γ (IFN-
γ), interleukin (IL)-10, IL-6, and the IL-8 mouse homolog
chemokine KC or chemokine (C-X-C motif) ligand 1 (CXCL1)
concentrations were measured with commercially available
enzyme-linked immunosorbent assay (ELISA) kits following
the manufacturer’s recommendations (R&D Systems, MN,
United States). TNF-α (Mouse TNF-α ELISA Kit, sensitivity:
1.5 pg/ml), IFN-γ (Mouse IFN-gamma Quantikine ELISA Kit,
sensitivity: 2 pg/ml), IL-6 (Mouse IL-6 Quantikine ELISA Kit,
sensitivity: 1.8 pg/ml), IL-10 (Mouse IL-10 Quantikine ELISA
Kit, sensitivity: 5.2 pg/ml), and CXC1 (Mouse CXCL1/KC DuoSet
ELISA, sensitivity 2.3 pg/ml) kits were used.
Intestinal Tissue Injury
Intestinal tissue injury was evaluated as described previously
(Elean et al., 2020). Briefly, small intestine samples from all
experimental groups were excised and washed out with PBS.
Then, tissues were immersed in 4% (v/v) formalin saline
solution. Once fixed, samples were dehydrated and embedded
in Histowax (Leica Microsystems Nussloch GmbH, Nussloch,
Germany) at 56◦C. Finally, intestines were cut into 4 µm
serial sections and stained with hematoxylin-eosin for light
microscopy examination. All slides were coded and evaluated
blindly. A semiquantitative scoring index was used to evaluate
alterations in the intestine. The presence/absence and intensity
of edema, epithelial injury, degranulation of Paneth cells and
inflammation were considered. Each parameter was rated on a
point damage scale from 1 to 4 (1, absence; 2, slight; 3, moderate;
4, severe alteration) and the final score results were expressed
as the sum of the individual scores given to each parameter
(Torres et al., 2017).
Statistical Analyses
Statistical analyses were performed with the software package
Minitab 17 (Minitab Inc.) using ANOVA general linear models
followed by Tukey’s post hoc test where p < 0.05 was
considered significant. Unless otherwise specified, all reported
values were the means of three independent trials ± standard





In order to develop GABA-enriched fermented berry juices,
firstly, we studied the growth of L. brevis CRL 2013 in blueberry
and strawberry pulp-free juices supplemented with 267 mM
MSG. As control, the strain was grown in the same juices without
extra supplementation. GABA production was not observed in
the fermented berry juices supplemented only with MSG (data
not shown). Thus, growth parameters and GABA production
were evaluated in the pulp-free juices supplemented with MSG
and YE or tryptein. Initial pH was either adjusted to ca. 6.5 using
0.1 M NaHCO3 or left unmodified and the fermentation was
monitored for 7 days at 30◦C. No significant differences in cell
density and pH time course were observed between juices with
adjusted and unadjusted initial pH (data not shown). In both
YE and tryptein-supplemented media, L. brevis CRL 2013 was
able to reach a sustained growth (Figure 1). YE-supplemented
juices presented higher cell densities than those observed for
the tryptein-supplemented ones (Figure 1). In the first 24 h of
fermentation, the cell growth was accompanied by a decrease in
the pH of the media independently of the initial pH. Thereby,
pH values for strawberry and blueberry juices sharply decreased
during the first 24 h and 48 h, reaching values of∼4.86 and∼4.75
for the YE supplemented strawberry (Figure 1A) and blueberry
juices (Figure 1B), respectively.
Although juices supplemented with tryptein allowed a
sustained growth of L. brevis CRL 2013, no increase in the
pH of the medium was observed and GABA was not detected
in the culture supernatants. Contrariwise, in strawberry juice
supplemented with YE (Figure 1A), GABA synthesis began after
24 h of fermentation whereas in blueberry juice (Figure 1B),
GABA became detectable only after 48 h. In both cases, GABA
production was accompanied by a concomitant increase of the
pH of the extracellular milieu (Figure 1). In YE-supplemented
juices GABA production progressed up to 168 h. Thus, the
highest productivity (262 mM GABA) was obtained after
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FIGURE 1 | Cell growth (green lines), pH (blue lines), and GABA production (cyan lines) by L. brevis CRL 2013 in MSG strawberry (A) and blueberry (B) juices
supplemented with yeast extract (•) or tryptein (H) at an initial pH of 6.5. Cell growth is expressed as ln x/x0, where x0 is initial biomass, and x is biomass at the
indicated time. All values are means ± standard deviations from at least three separate experiments.
fermenting strawberry juice supplemented with YE for 168 h,
being GABA yield significantly higher in strawberry juices than
in the blueberry ones. No interference by other compounds was
found during GABA determinations and GABA was not detected
in any of the intact juices without MSG supplementation. Based
on these results, we selected the GABA-enriched fermented
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strawberry juice (FSJ) for 72 h as a model for further functional
studies. This juice contains about 2.7× 107 CFU/ml and a GABA
concentration of around 140 mM, which would be compatible
with the doses reported by Taranukhin et al. (2017) to carry out
functional assays.
Anti-inflammatory Effect of
GABA-Enriched FSJ on Mouse
Macrophages
We aimed to evaluate in vitro whether the GABA-enriched FSJ
was able to modulate the response of macrophages to TRL4
activation. For this purpose, we first studied whether the GABA-
enriched FSJ was able to exert any detrimental effect on RAW
264.7 macrophages by evaluating their viability (Supplementary
Figure 1). Then, mouse macrophages were stimulated with
GABA-enriched FSJ that was diluted until reaching a GABA
concentration equal to 1 mM. This final amount of GABA was
selected considering that this concentration was the optimal
to modulate the expression of inflammatory factors in RAW
264.7 cells (Han et al., 2007). In addition, NFSJ as well
as stimulations with 0.1 and 1.0 mM GABA were used for
comparisons. All the treatments yielded survival percentages
around 82% (Supplementary Figure 1), which allowed the
use of these samples for pro-inflammatory marker expression
studies. No significant differences were observed in the viability
of macrophages after their treatment with both fermented and
non-fermented juices or GABA alone.
The potential anti-inflammatory properties of the GABA-
enriched FSJ were assessed through the evaluation of the relative
expression of a key factor that is up-regulated in response
of TLR4 activation: COX-2 (Lee et al., 2003). As expected,
control macrophages stimulated with LPS significantly increased
the expression levels of cox-2 (Figure 2). The treatment of
macrophages with 0.1 mM GABA did not induce remarkable
effects in the response of these cells to the activation of TLR4,
however, when GABA was used at a concentration of 1 mM, a
significant reduction of cox-2 transcripts was observed compared
to LPS-challenged control cells (Figure 2). Similarly, mouse
macrophages treated with GABA-enriched FSJ had significantly
lower levels of cox-2 than LPS-challenged controls. Moreover, the
expression of cox-2 in macrophages treated with GABA-enriched
FSJ was not different from that found in cells stimulated with
1 mM GABA. No significant differences in the expression of cox-
2 were observed when control macrophages and cells treated
with NFSJ were compared (Figure 2). These results indicated
that the GABA-enriched FSJ obtained after fermentation with
the L. brevis CRL 2013 strain has the potential to beneficially
modulate the TLR4-mediated inflammation.
Effect of GABA-Enriched FSJ in Mice
Cytokine’s Profile
We next aimed to evaluate in vivo the effect of the GABA-
enriched FSJ. For this purpose, mice were treated with the
GABA-enriched FSJ or the diluted GABA-enriched FSJ (1:2)
during 3 days. In addition, to assess the potential intrinsic
immunomodulatory effect of the bacterial strain, a group of
animals treated only with L. brevis CRL 2013 was included.
Animals treated with NFSJ or NFSJ supplemented with YE
were also used for comparisons. When the levels of the pro-
inflammatory factors TNF-α, IL-6 and CXCL1 were evaluated
in the peritoneal cavity after treatments with GABA-enriched
FSJ, diluted GABA-enriched FSJ or L. brevis CRL 2013 no
significant differences were found between these groups or the
untreated control mice (Figure 3). Similarly, no differences in
the levels of intestinal and serum TNF-α were detected when
GABA-enriched FSJ- or CRL 2013-treated mice were compared
to controls (Figure 4). Of note, mice receiving GABA-enriched
FSJ or L. brevis CRL 2013 had higher levels of peritoneal IFN-γ
and IL-10 than control animals, an effect that was not observed
in mice receiving the diluted GABA-enriched FSJ (Figure 3). In
addition, mice treated with GABA-enriched FSJ or L. brevis CRL
2013 had higher levels of intestinal IFN-γ and IL-10 than control
animals (Figure 4). The CRL 2013 strain was more efficient
than the GABA-enriched FSJ and the diluted FSJ to increase
the intestinal IFN-γ. Interestingly, the GABA-enriched FSJ was
more efficient than L. brevis CRL 2013 and the diluted FSJ to
increase the intestinal IL-10. Only L. brevis CRL 2013 was able
to increase the levels of serum IFN-γ when compared to controls
(Figure 4). In addition, although the treatments with CRL 2013
and GABA containing juices increased the levels of serum IL-10,
the treatment with non-diluted GABA-enriched FSJ was more
efficient to induce this effect (Figure 4). Animals treated with
NFSJ or NFSJ supplemented with YE had values of peritoneal
(Figure 3), intestinal and serum cytokines (Figure 4) that were
not different from untreated control mice.
Anti-inflammatory Effect of
GABA-Enriched FSJ in Mice
Finally, we aimed to confirm our in vitro findings by evaluating
in vivo the anti-inflammatory effects of GABA-enriched FSJ
in the context of TRL4 activation. Then, animals received
the five treatments described before and on the day 4 they
were challenged with an intraperitoneal injection of LPS. The
activation of TLR4 significantly increased levels of the pro-
inflammatory factors TNF-α, IL-6 and CXCL1 as well as IFN-γ
and IL-10 in the peritoneal cavity (Figure 5). Mice receiving
the GABA-enriched FSJ showed the most remarkable differences
in the peritoneal cytokines ’profile. This group of mice had
significantly lower levels of TNF-α, IL-6 and CXCL1 and higher
concentrations of IFN-γ and IL-10 when compared to LPS-
challenged controls. The treatment with diluted GABA-enriched
FSJ was also capable of reducing the levels of inflammatory factors
and slightly increases IL-10; however, it did not achieve the effect
induced by the non-diluted GABA-enriched FSJ (Figure 5). Of
note, mice treated with L. brevis CRL 2013 had reduced levels
of TNF-α and CXCL1 that were similar to those found in the
diluted GABA-enriched FSJ group. The CRL 2013 strain was not
able to modify the levels of IL-6 when compared to controls. In
addition, mice treated with L. brevis CRL 2013 had increased
levels peritoneal IFN-γ and IL-10. Whereas the levels of IFN-γ
were similar to those found in the GABA-enriched FSJ group, the
levels of IL-10 were significantly lower (Figure 5).
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FIGURE 2 | Effects of GABA, non-fermented strawberry juice (NFSJ) and GABA-enriched fermented strawberry juice (FSJ) on cox-2 expression in RAW 264.7 cells
stimulated by LPS. After treatment with the indicated compounds for 1 h, cells were stimulated for 4 h with LPS (1 µg/ml). Total RNA was isolated, and then
RT-qPCR was used to measure the mRNA levels of cox-2 with β-actin expression as an internal control. Data represent means ± standard error of three
independent experiments. Means for each bar without a common letter differ significantly. Significance with Tukey’s HSD post hoc test following a one-way ANOVA
is indicated as p < 0.05.
In addition, the GABA-enriched FSJ was able to induce a
significant reduction of intestinal and serum TNF-α, and to
increase IFN-γ and IL-10 when compared to LPS-challenged
controls (Figure 6). The treatments with L. brevis CRL 2013 and
diluted GABA-enriched FSJ were also capable of increasing and
reducing the levels of IL-10 and TNF-α, respectively. However,
the concentrations of both cytokines in those groups did not
reach the values found in the non-diluted FSJ group (Figure 6).
On the other hand, the treatment of mice with the CRL 2013
strain induced a similar increase of intestinal and serum IFN-γ
than the observed in the GABA-enriched FSJ (Figure 6). Animals
treated with NFSJ or NFSJ supplemented with YE had values of
peritoneal (Figure 5), intestinal and serum cytokines (Figure 6)
that were not different from control mice in the context of
TLR4-induced inflammation (Figure 5).
The histopathological examination of the intestinal tissue
revealed that LPS administration was capable of increasing the
damage score from 4 (normal score) up to ∼14 (Figure 7).
Indeed, the LPS challenge induced intestinal edema, epithelial
injury, infiltration of inflammatory cells and a moderate
degranulation of Paneth cells. The treatments with non-diluted
and diluted GABA-enriched FSJ as well as with L. brevis CRL
2013 significantly reduced the scores of intestinal injury. Of
note, although there were not statistical significant differences
between the score of these three groups, mice receiving the non-
diluted GABA-enriched FSJ had a tendency to lower infiltration
of inflammatory cells in the intestinal mucosa. Animals treated
with NFSJ or NFSJ supplemented with YE had values of
intestinal injury scores that were not different from control
mice (Figure 7).
DISCUSSION
Gamma-aminobutyric acid is a non-protein amino acid that
has been extensively described as a health-promoting functional
compound (Diana et al., 2014; Quílez and Diana, 2017).
Considering that berries contain powerful antioxidants and other
functional compounds, biotechnological approaches are being
currently used to increase the content of specific health-related
compounds in these fruits and its derivatives (Battino et al.,
2009). Since LAB are currently the most interesting group of
microorganisms capable of producing GABA at high yields, there
is an opportunity to isolate and identify GABA producing strains
to be used as starter cultures in the design and development
of novel functional fermented foods or as probiotics. In this
regard, based on previous screenings performed in our laboratory
(Cataldo et al., 2020), L. brevis CRL 2013 was selected as the
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FIGURE 3 | Effect of L. brevis CRL 2013, GABA-enriched strawberry fermented juice (FSJ) and diluted (d) GABA-enriched FSJ on peritoneal cytokines and
chemokines in Balb/c mice. Animals treated with NFSJ or NFSJ supplemented with YE were used for comparisons. Results are expressed as mean ± SD. Means
for each bar without a common letter differ significantly. Significance with Tukey’s HSD post hoc test following a one-way ANOVA is indicated as p < 0.05.
most appropriate GABA-producing LAB for the manufacture of
a functional fermented beverage.
Since lactic acid fermentation has a remarkable role in
improving the intrinsic functional and nutritional properties
of many vegetable food matrixes (Di Cagno et al., 2016) and
due to its well-known positive effects in traditional fermented
foods, in this work both blueberry and strawberry juices were
subjected to a process of lactic fermentation by L. brevis
CRL 2013. The acidification rate during both strawberry and
blueberry fermentation was similar to that observed by Kim
et al. (2009) when fermenting a black raspberry juice with
L. brevis GABA 100. In order to set the vegetable matrix for
the fermentation, additional sources of nitrogen were added to
the juices, an alternative also used by Di Cagno et al. (2010)
when fermenting a grape must. A survey of the genome of
CRL 2013 strain (Accession number: NZ_MZMW00000000.1)
confirms that L. brevis CRL 2013 lacks the gene encoding cell
envelope associated proteinase. Since L. brevis CRL 2013 is a non-
proteolytic strain, the growth recovery was probably due to the
presence of several free amino acids and peptides in both YE and
tryptein, which are essential for bacterial growth (Hebert et al.,
2001). Although GABA synthesis began earlier in the strawberry
juice, it continued to progress up to 168 h in both juices, reaching
a maximum GABA level of 262 mM GABA. In this sense,
GABA in raspberry juices fermented by L. brevis GABA 100 at
30◦C reached the maximum levels on the 12th day (Kim et al.,
2009). To our knowledge, this is the first report regarding the
GABA-enrichment of blueberry and strawberry juices by lactic
acid fermentation.
The functional in vitro and in vivo studies performed in this
work allow us to reach three important conclusions: (a) the
GABA-enriched FSJ produced with L. brevis CRL 2013 is able
to differentially modulate the inflammatory response induced by
the activation of TLR4; (b) the immunoregulatory effect induced
by the GABA-enriched FSJ depends on its concentration, and
(c) the intrinsic immunomodulatory properties of the CRL 2013
strain may contribute to the modulatory effect of the GABA-
enriched FSJ.
In our hands, the GABA-enriched FSJ was capable of
reducing the expression of the inflammatory marker cox-2 in
RAW macrophages activated by TLR4 stimulation. In line with
our results, it was reported previously that GABA is capable
of inhibiting immune cells activation by modulating NF-kB
pathway, thus diminishing the production of inflammatory
mediators such as TNF-α, COX-2 and iNOS (Jin et al., 2013;
Prud’homme et al., 2015). In addition, the ability of GABA to
inhibit the in vitro release of IL-6 and IL-12 by LPS-stimulated
peritoneal macrophages was also reported by Reyes-García et al.
(2007). Besides, it was shown that a GABA-enriched pepino
extract obtained after fermentation by L. brevis BCRC 12310 was
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FIGURE 4 | Effect of L. brevis CRL 2013, GABA-enriched strawberry fermented juice (FSJ) and diluted (d) GABA-enriched FSJ on intestinal and serum cytokines
and chemokines in mice. Animals treated with NFSJ or NFSJ supplemented with YE were used for comparisons. Results are expressed as mean ± SD. Means for
each bar without a common letter differ significantly. Significance with Tukey’s HSD post hoc test following a one-way ANOVA is indicated as p < 0.05.
able to inhibit the expression of TNF-α in LPS-induced RAW
264.7 macrophages (Chang et al., 2016).
To the best of our knowledge, the immunoregulatory effects
of GABA-enriched products after fermentation with lactobacilli
have not been studied in depth within in vivo models. For
this reason, we also aimed in this work to demonstrate in vivo
the potential immunomodulatory effect of the GABA-enriched
FSJ obtained after the fermentation with the CRL 2013 strain.
We were able to demonstrate that the oral treatment with the
GABA-enriched FSJ was capable of modulating the inflammatory
response triggered by the activation of TRL4 at the intestinal
mucosa, in the peritoneal cavity and at the systemic level. The
GABA-enriched FSJ reduced the production of TNF-α, IL-6
and CXCL1 as well as improved the levels of IL-10 in the
three body compartments analyzed (Figure 8). Activation of
TLR in macrophages after the binding of its ligand induce a
signaling cascade that culminates in the expression and secretion
of various cytokines, chemokines, and other inflammatory factors
which signal and prime neighboring immune cells. Although
necessary to confer protection against invading pathogens, the
TLR-mediated inflammation needs to be tightly controlled at
mucosal surfaces such as the intestinal tissue to avoid exaggerated
inflammatory responses and damage. Then, we speculated
that the differential cytokine profile induced by the GABA-
enriched FSJ in the intestinal mucosa after TLR4 activation
would be capable of protecting against the inflammatory
damage. The histological studies performed here, demonstrated
that this statement was correct since a significantly lower
intestinal damage score, mainly related to a lower infiltration
of inflammatory cells, was observed in mice treated with the
GABA-enriched FSJ when compared to controls.
Interestingly, it has been shown that GABA-enriched products
obtained by fermentation with lactobacilli can modulate not only
the immune response mediated by macrophages but also by other
immune cells such as lymphocytes. In this regard, it was recently
reported that live bacteria-free supernatant collected from the
GABA-producing L. brevis BGZLS10-17 is able to differentially
modulate the proliferation, the MHCII and CD80 expression
and the production of IFN-γ and IL-17 in concanavalin
A-stimulated mesenteric lymph node lymphocytes (Bajić et al.,
2020). Furthermore, GABA-containing supernatants were able to
increase the expression of immunoregulatory molecules Foxp3,
IL-10, and TGF-β in immune cells. These in vitro findings
correlated with the in vivo ability of the GABA producing
BGZLS10-17 strain to protect against inflammatory-induced
destruction of intestinal barrier in an experimental autoimmune
encephalomyelitis model (Sokovic Bajic et al., 2019). These
results indicate that it would be of great importance to study
the immunomodulatory effect of the CRL 2013-derived GABA-
enriched FSJ in the context of other inflammatory challenges, to
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FIGURE 5 | Effect of L. brevis CRL 2013, GABA-enriched strawberry fermented juice (FSJ) and diluted (d) GABA-enriched FSJ on peritoneal cytokines and
chemokines in mice challenged with LPS. Animals treated with NFSJ or NFSJ supplemented with YE were used for comparisons. Results are expressed as
mean ± SD. Means for each bar without a common letter differ significantly. Significance with Tukey’s HSD post hoc test following a one-way ANOVA is indicated as
p < 0.05.
know its potential to be applied in the prevention or treatment of
autoimmune and inflammatory diseases.
In the present study, we also observed a correlation between
GABA concentration and the degree of repression of cox-2
in murine macrophages activated by TLR4 stimulation; 1 mM
GABA pretreatment presented inhibitory influence whereas
0.1 mM GABA was not enough concentration to achieve
a significant inhibition. This dose-dependent inhibition is in
agreement with a previous result in which 1 mM GABA was
the optimal concentration to reach the highest inhibition on the
expression of TNF-α and iNOS in LPS-induced RAW 264.7 cells
(Han et al., 2007). Furthermore, these in vitro results are in line
with the in vivo studies performed here that demonstrated the
reduced ability of the diluted GABA-enriched FSJ to modulate
the inflammatory response triggered by TLR4 activation in mice
when compared to non-diluted GABA-enriched FSJ. It should be
noted that another possibility for the lower ability of the diluted
GABA-enriched FSJ to modulate the innate immune response
could be related to the dilution of the lactobacilli dose. It would
be interesting to study in the future the effect of different doses
of L. brevis CRL 2013 and concentrations of GABA-enriched FSJ
to modulate the TLR4-triggered inflammation to find the optimal
doses that exert their beneficial effects.
Interestingly, the oral administration of L. brevis CRL 2013
to mice was able to increase the intestinal, peritoneal and serum
levels of IFN-γ and IL-10. Several studies have reported the
beneficial effects of immunomodulatory lactobacilli and have
highlighted that the most remarkable effect of lactobacilli on the
intestinal cytokine profile is the increase of TNF-α, IFN-γ, and
IL-10 (Salva et al., 2010; Marranzino et al., 2012; Villena et al.,
2012). Moreover, it is considered that through the release of
intestinal TNF-α and IFN-γ, immune enhancing lactobacilli are
capable of stimulating the activities of peritoneal macrophages.
In this regard, we have shown that the oral administration of
the highly immune enhancing strains Lacticaseibacillus casei
CRL431 (formerly known as Lactobacillus casei CRL431),
Lactiplantibacillus plantarum CRL1506 (formerly known as
Lactobacillus plantarum CRL1506), and Lacticaseibacillus
rhamnosus CRL1505 (formerly known as Lactobacillus
rhamnosus CRL1505) increase the production of TNF-α,
IFN-γ, and IL-10 in the intestine after their oral administration
(Salva et al., 2010; Marranzino et al., 2012; Villena et al., 2012).
More recently, we observed that immunomodulatory strains
such as Limosilactobacillus fermentum UCO-979C (formerly
known as Lactobacillu fermentum UCO-979C) significantly
improved the production of intestinal IFN-γ, and IL-10 but not
of TNF-α (Garcia-Castillo et al., 2019). This probiotic strain is
not a highly stimulating strain of the immune system, but rather
behaves like an immunoregulatory strain, moderately stimulating
effector responses and inducing anti-inflammatory responses.
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FIGURE 6 | Effect of L. brevis CRL 2013, GABA-enriched strawberry fermented juice (FSJ) and diluted (d) GABA-enriched FSJ on intestinal and serum cytokines
and chemokines in mice challenged with LPS. Animals treated with NFSJ or NFSJ supplemented with YE were used for comparisons. Results are expressed as
mean ± SD. Means for each bar without a common letter differ significantly. Significance with Tukey’s HSD post hoc test following a one-way ANOVA is indicated as
p < 0.05.
FIGURE 7 | Effect of L. brevis CRL 2013, GABA-enriched strawberry fermented juice (FSJ) and diluted (d) GABA-enriched FSJ on intestinal damage in mice
challenged with LPS. Animals treated with NFSJ or NFSJ supplemented with YE were used for comparisons. Score values were calculated considering the
presence/absence and intensity of edema, epithelial injury, degranulation of Paneth cells and inflammation. Results are expressed as mean ± SD. Means for each
bar without a common letter differ significantly. Significance with Tukey’s HSD post hoc test following a one-way ANOVA is indicated as p < 0.05.
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FIGURE 8 | Proposed mechanism for the immunomodulatory effect of Levilactobacillus brevis CRL 2013 and GABA in the immune response triggered by the
activation of TLR4.
The results obtained in this work, allow concluding that the
CRL 2013 strain belongs to this group of lactic acid bacteria. In
fact, L. brevis CRL 2013-treated mice were able to differentially
regulate the response to TLR4 by reducing the production of
TNF-α and CXCL1, and further enhancing IL-10 (Figure 8).
Some studies have described immune enhancing L. brevis
strains. The treatment of macrophages with L. brevis KCTC
12777BP increased their phagocytic activity and the production
of TNF-α, IL-6, and nitric oxide (Jeong et al., 2020).
L. brevis ZLB004 was capable of increasing IFN-γ concentration
enhancing the immune health status of weaned pigs (Liu
et al., 2015) while L. brevis ATCC 8287 reduced TGF-β1
and increased IL-6 expressions in the small intestine of pigs
(Lähteinen et al., 2014). However, no strains of L. brevis have
been described to possess a mixed stimulatory/anti-inflammatory
profile. Then, our results raise the question of whether L. brevis
CRL 2013 could be used by itself as an immunomodulatory
probiotic strain to exert beneficial effects in other immune-
related diseases. It should be noted that the intrinsic anti-
inflammatory activity of the CRL 2013 strain was increased
when it was administered together with GABA. However, it
is possible to rule out the effect of GABA in the bacteria
administered alone, since the concentrations of GABA that this
bacterium can produce in situ in the intestinal mucosa are
far below those necessary to obtain the immunomodulatory
effect, as demonstrated by our comparative studies using non-
diluted and diluted GABA-enriched FSJ. Then, it would also
be of great value to investigate which bacterial molecule(s) are
responsible for the intrinsic immunomodulatory effect observed
in the CRL 2013 strain.
In conclusion, L. brevis CRL 2013, a major GABA producer
among the strains evaluated in our laboratory, was used
for the formulation of a GABA-enriched fermented berry
juice. Considering that a significantly higher GABA yield
was observed in fermented strawberry than in fermented
blueberry juice, the former one was selected for further studies.
The highest GABA production was obtained by fermenting
the YE-supplemented strawberry juice with L. brevis CRL
2013 as starter culture. The GABA-enriched strawberry juice
modulated the expression of cox-2 in LPS stimulated RAW 264.7
macrophages and exerted a remarkable anti-inflammatory effect
in vivo in the context of TLR4 activation. Our observations
strikingly support the potential of GABA and GABA-enriched
strawberry fermented juices as promising functional foods to help
ameliorate the exacerbated inflammatory response of chronic
inflammatory diseases in addition to the other well-known
GABA positive properties such as diuretic, antihypertensive,
hypoglycemic and antidepressant compound. To our knowledge,
this is the first report of a bio-enriched fermented strawberry
juice capable of positively modulating the TLR4-mediated
inflammatory response.
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